A practical reference on Dihexa: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-25 and is reviewed periodically as new material appears.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
In addition to the specific amino acid codes, placeholders are used in cases where chemical or crystallographic analysis of a peptide or protein cannot conclusively determine the identity of a residue. They are also used to summarize conserved protein sequence motifs. The use of single letters to indicate sets of similar residues is similar to the use of abbreviation codes for degenerate bases.
== History == The use of iboga in African spiritual ceremonies was first reported by French and Belgian explorers in the 19th century, beginning with the work of French naval physician and explorer of Gabon Marie-Théophile Griffon du Bellay. The first botanical description of the Tabernanthe iboga plant was made in 1889. Ibogaine was first isolated from T. iboga in 1901 by Dybowski and Landrin and independently by Haller and Heckel in the same year using T. iboga samples from Gabon. Complete synthesis of ibogaine was accomplished by G. Büchi in 1966. Since then, several other synthesis methods have been developed. Use of low doses of ibogaine (e.g. 10–30 mg/day) as a stimulant and "anti-fatigue" drug in the treatment of conditions like "cardiac atony", neurasthenia, and convalescence was advocated by French researchers in 1905. From the 1930s to 1960s, ibogaine was sold in France as Lambarène, an extract of the Tabernanthe manii plant, and promoted as a mental and physical stimulant. It was formulated at doses of 200 mg extract containing low doses of 4 to 8 mg ibogaine per tablet. The drug enjoyed some popularity among post-World War II athletes. Lambarène was withdrawn from the market in 1966 when the sale of ibogaine-containing products became illegal in France. Another formulation was Iperton, which contained Tabernanthe iboga extract 40 mg per dose unit. In 2008, Mačiulaitis and colleagues stated that in the late 1960s, the World Health Assembly classified ibogaine as a "substance likely to cause dependency or endanger human health". The U.S.
== Production == Yeast extracts in general are produced in three steps: fermentation (growing the yeast), disruption (breaking of the cells), and separation (to keep the soluble part). Although the vast majority of yeast extract spreads are made using von Liebig's traditional approach of heat-autolysis using surplus yeast from beer brewing, other methods do exist for producing specialized types. In terms of fermentation, spent beer yeast is commonly contaminated with the bitter compounds from hops, requiring a "debittering" step to wash out most of this undesired flavor. Yeast from other sources are not affected by this issue. Spent brewer's yeast is also quite biodiverse, containing yeasts other than traditional Saccharomyces cerevisiae and sometimes beer spoilage-causing lactic acid bacteria too. For disruption of the cell, some physical and chemical methods may be used in place of the heat-autolysis process. Doing so may allow specific compounds to be extracted or to produce an extract without the hydrolysis of cell contents (as in autolysis) happening. Autolysis can be assisted with added enzymes; for example, additional nuclease would enhance the release of nucleosides from RNA. Separation removes insoluble parts, mainly the yeast's cell wall, from the extract. Cell wall can be separated into two commercially useful parts: the glucans as "yeast β-glucan" and the mannans further processed into mannan-oligosaccharide (MOS). The product is finally concentrated by drying, into a thick paste or a dry powder.
On 16 May 2023, three weeks after Tangaraju was put to death, 36-year-old Muhammad Faizal Mohd Shariff, a Singaporean who was found guilty in 2019 of trafficking 1.5 kg of marijuana was reported to have lost his final appeal to commute his sentence. A day after losing his appeal, Muhammad Faizal was hanged at dawn on 17 May 2023, with the authorities confirming his execution despite not naming Muhammad Faizal out of consideration for his family's need for privacy. Two executions of a 56-year-old man and 45-year-old woman (both convicted of drug offences) were scheduled to take place on 26 July and 28 July 2023 respectively; the female offender Saridewi Djamani was believed to be the first woman to be executed in 19 years, as the last known execution of a woman took place on 19 March 2004, when 37-year-old Yen May Woen was put to death for diamorphine trafficking. The 56-year-old male drug offender Mohd Aziz Hussain, as well as Saridewi, were both hanged as scheduled, becoming the third and fourth persons respectively to be executed in Singapore in the year of 2023. On 3 August 2023, Singapore carried out the hanging of Mohamed Shalleh Abdul Latiff, a 39-year-old Singaporean and former delivery driver found guilty of trafficking 54.04g of diamorphine in 2016. In total, five executions, all once again for drug trafficking, took place in the year 2023. When 35-year-old Ahmed Salim was hanged on 28 February 2024 for murdering his former fiancée, he was the first criminal hanged in Singapore in that year.
=== Beginnings of molecular cytogenetics === In the 1980s, advances were made in molecular cytogenetics. While radioisotope-labeled probes had been hybridized with DNA since 1969, movement was now made in using fluorescent-labeled probes. Hybridizing them to chromosomal preparations using existing techniques came to be known as fluorescence in situ hybridization (FISH). This change significantly increased the usage of probing techniques as fluorescent-labeled probes are safer. Further advances in micromanipulation and examination of chromosomes led to the technique of chromosome microdissection whereby aberrations in chromosomal structure could be isolated, cloned, and studied in ever greater detail.
Sources: en.wikipedia.org
==== Competitive ==== A competitive inhibitor and substrate cannot bind to the enzyme at the same time. Often competitive inhibitors strongly resemble the real substrate of the enzyme. For example, the drug methotrexate is a competitive inhibitor of the enzyme dihydrofolate reductase, which catalyzes the reduction of dihydrofolate to tetrahydrofolate. The similarity between the structures of dihydrofolate and this drug are shown in the accompanying figure. This type of inhibition can be overcome with high substrate concentration. In some cases, the inhibitor can bind to a site other than the binding-site of the usual substrate and exert an allosteric effect to change the shape of the usual binding-site.
== History == The condition was first described in 1561 in correspondence between Andreas Vesalius and Gabriele Falloppio and separately by Gabriele Falloppio. The condition is named after François Gigot de la Peyronie, who described it in 1743. Peyronie was the personal physician of King Louis XV and cofounder of the Académie Royale de Chirurgie, which was later included in the French Académie nationale de médecine.
while fresh citrus (particularly lemons) cured scurvy, lime juice that had been exposed to light, air, and copper tubing did not – thus undermining the theory that citrus cured scurvy; fresh meat (especially organ meat and raw meat, consumed in arctic exploration) also cured scurvy, undermining the theory that fresh vegetable matter was essential to preventing and curing scurvy; increased marine speed via steam shipping, improved nutrition on land, reduced the incidence of scurvy – and thus the ineffectiveness of copper-piped lime juice compared to fresh lemons was not immediately revealed. In the resulting confusion, a new hypothesis was proposed, following the new germ theory of disease – that scurvy was caused by ptomaine, a waste product of bacteria, particularly in tainted tinned meat. Infantile scurvy emerged in the late 19th century because children were fed pasteurized cow's milk, particularly in the urban upper class. While pasteurization killed bacteria, it also destroyed vitamin C. This was eventually resolved by supplementing with onion juice or cooked potatoes. Native Americans helped save some newcomers from scurvy by directing them to eat wild onions.
Kraven and Lucian turn on each other, and the former tells Selene that Viktor was the one who really murdered her family and only spared and mentored her due to being reminded of his daughter. Selene is forced to bite a fatally injured Michael, hoping to make him a vampire-werewolf hybrid, while Kraven shoots Lucian, killing him. When Viktor arrives at the Lycans' lair after the battle, he admits to murdering Selene's parents and killing his daughter. He also insists that he killed Sonja for the good of his people and reveals she was pregnant with Lucian's child, an abomination in the eyes of the two species. Lastly, he claims that he made Selene immortal because he loved her and proceeds to fight the hybrid Michael. Initially overwhelmed by Michael’s strength, Viktor eventually gets the upper hand and attempts to strangle him. Selene rouses from her disorientation and kills Viktor by beheading him with his sword. Now enemies of both vampires and Lycans, Selene and Michael flee the Lycans' lair together. Back at the vampires' mansion, Marcus, now the sole surviving vampire elder, awakens as a hybrid after Singe's blood seeps into his sarcophagus.
Within the United States, the Patient Protection and Affordable Care Act of 2010 created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. Researchers are optimistic that the introduction of biosimilars will reduce medical expenses to patients and the healthcare system.
Sources: en.wikipedia.org
(2026) study the anatomy of ulna and femur or Sahelanthropus tchadensis, interpreted as indicative of presence of adaptations to bipedalism in spite of similarities in size and geometric morphometric shape to bones of chimpanzees. De Jager et al. (2026) study the frequency, position, and variability of cortical sulcal imprints in endocasts of extant chimpanzees and bonobos, providing a comparative resource for the studies of the brain evolution based on hominin fossils. Dunbar (2026) reevaluates data from the study of Deaner & Nunn (1999), finds evidence of changes in brain size following increases in body size in the evolution of primates but in a more complicated way that suggested by the original brain lag hypothesis, with an increase in body size followed by a progressively greater increase in brain size, and finds evidence of such evolution of brain and body size in hominins.
== Diagnosis == Perichondral hematoma and consequently cauliflower ear are diagnosed clinically. This means that the medical provider will make the diagnosis by using elements of the history of the injury (examples: participation in contact sports, trauma to the ear, previous similar episodes) and combine this with findings on physical exam (examples: tenderness to the area, bruising, deformation of the ear contours) to confirm the diagnosis and decide on the appropriate treatment for the patient.
=== Biochemistry === Guanidine exists protonated, as guanidinium, in solution at physiological pH. Guanidinium chloride (also known as guanidine hydrochloride) has chaotropic properties and is used to denature proteins. Guanidinium chloride is known to denature proteins with a linear relationship between concentration and free energy of unfolding. In aqueous solutions containing 6 M guanidinium chloride, almost all proteins lose their entire secondary structure and become randomly coiled peptide chains. Guanidinium thiocyanate is also used for its denaturing effect on various biological samples. Recent studies suggest that guanidinium is produced by bacteria as a toxic byproduct. To alleviate the toxicity of guanidinium, bacteria have developed a class of transporters known as guanidinium exporters or Gdx proteins to expel the extra amounts of this ion to the outside of the cell. Gdx proteins are highly selective for guanidinium and mono-substituted guanidinyl compounds and share an overlapping set of non-canonical substrates with drug exporter EmrE.
All branches connect at Jamaica station except the Port Washington Branch. Jamaica station also connects to Airtrain JFK for service to John F. Kennedy International Airport. Normally, the LIRR uses tracks 17 to 21 exclusively and shares tracks 13 to 16 with Amtrak and NJT. The LIRR uses tracks 11 and 12 on rare occasions.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.